What is the total market value of HLA Typing Transplant Market report?

HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) - Global Forecast to 2025


johnny andrew

a year ago | 1 min read

Expected Revenue Growth:

[193 Pages Report] The HLA typing for the transplants market
is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a
CAGR of 6.7%.

Download PDF Brochure:

What This Report Will Provide?

The study involved four major activities in estimating the
current size of the HLA typing for the transplants market. Exhaustive secondary
research was conducted to collect information on the market and its different

The next step was to validate these findings, assumptions,
and sizing with industry experts across the value chain through primary
research. Both top-down and bottom-up approaches were employed to estimate the
total market size.

Major Growth Boosters:

The demand for transplant diagnostic products for HLA typing
is expected to grow mainly due to factors such as technological advancements,
the growing number of diagnostic centers & hospitals, increased
applications in patient profiling, and rising public-private investments to
support product development.

Regional Growth Analysis:

North America accounted for the largest share of the HLA
typing for the transplants market, followed by Europe. This can primarily be
attributed to the continuous commercialization of innovative transplant
diagnostic products (includes HLA typing) coupled with ongoing advancements in
the field of genomics and proteomics, recent discovery genetic biomarkers &
their clinical role in immunoassay testing, and the increasing prevalence of
chronic and communicable diseases.

Key Market Players

Thermo Fisher Scientific, Inc. (US), QIAGEN N.V.
(Netherlands), Illumina (US), CareDx, Inc. (US), and Immucor, Inc. (US). Others
are Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland),
Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon
(Hungary), Becton, Dickinson and Company (US), Fujirebio, Inc. (Japan), and TBG
Diagnostics Ltd. (Australia)

Thermo Fisher Scientific is the top player in the
global HLA typing for the transplants market. The company offers various
diagnostic imaging modalities and services for transplant diagnostic procedures
(includes HLA typing) in the market.

Key Questions Addressed by the Report:

·What are the growth opportunities related to the
adoption of HLA typing for transplant products across significant regions in
the future?
Emerging countries show immense opportunities
for the growth and adoption of HLA typing for transplant instruments, related
reagents & consumables, and software. Will this scenario continue in the
next five years?
Where will the advancements in products offered
by various companies take the industry in the mid- to long-term?

What are the newest trends and advancements in
the HLA typing for the transplants market?

Request Sample Report:


Created by

johnny andrew







Related Articles